Predictors for mortality of inpatients of COVID-19 in Mumbai


  • Prasad T. Dhikale Department of Community Medicine, HBTMC and Dr RNCH, Mumbai, Maharashtra, India
  • Smita S. Chavhan Department of Community Medicine, HBTMC and Dr RNCH, Mumbai, Maharashtra, India
  • Balkrishna B. Adsul Department of Community Medicine, LTMGH and MC, Sion, Mumbai, Maharashtra, India
  • Kirti V. Kinge Department of Community Medicine, HBTMC and Dr RNCH, Mumbai, Maharashtra, India
  • Chinmay N. Gokhale Department of Community Medicine, HBTMC and Dr RNCH, Mumbai, Maharashtra, India
  • Aniket R. Ingale Department of Community Medicine, HBTMC and Dr RNCH, Mumbai, Maharashtra, India



COVID-19, Mortality, Comorbidities, Tertiary care hospital


Background: The estimation of risk factors for death can help in modifying the screening, treatment strategy and saving valuable lives. The published data about this topic from India is scarce. We aim to explore the risk factors of in-hospital deaths for COVID-19 patients.

Methods: This was a hospital-based cross-sectional study. All COVID-19 patients positive on reverse transcriptase–polymerase chain reaction (RTPCR) test who were admitted in this dedicated COVID hospital (DCH) in April to July 2020 and with definite outcome (death or discharge) till end of September 2020 were included in this study. To explore the risk factors associated with in-hospital death univariate and multivariate logistic regression models were used.

Results: Of the 6195 patients, 450 (7.26%) died. Age 40-60 years [AOR (CI)=4.53 (2.71-7.58)], age >60 years [AOR (CI)=17.42 (10.55-28.75)], suffering from diabetes mellitus [AOR (CI)=2.08 (1.66-2.6)], cardiovascular diseases [AOR (CI)=1.57 (1.14-2.17)], hypertension [AOR (CI)=1.43 (1.14-1.8)], chronic kidney diseases [AOR (CI)=2.78(2.02-3.82)] were found to be significant predictors of death after adjusting for potential confounders.

Conclusions: Age >40 years, diabetes mellitus, cardiovascular diseases, hypertension, chronic kidney diseases are the independent predictors for mortality in COVID-19. These high risk groups should be given special attention for screening and treatment.


Report of COVID-19 cases. Medical Education and Drugs Department. 2021.

Ministry of Health & Family Welfare Directorate General of Health Services EMR Division. Guidance document on appropriate management of suspect/confirmed cases of COVID-19. Available at: Accessed on 15 January 2021.

Kumbhar M, Chavhan S, Adsul B. Seven Hills Dedicated Covid Hospital, Mumbai. Municipal Corporation of Greater Mumbai. 2020.

World Health Organization. Estimating mortality from COVID-19. Available at: Accessed on 15 January 2021.

Bhandari S, Singh A, Sharma R, Rankawat G, Banerjee S, Gupta V, Dube A, Kakkar S, Sharma S, Keswani P, Agrawal A. Characteristics, Treatment Outcomes and Role of Hydroxychloroquine among 522 COVID-19 hospitalized patients in Jaipur City: An Epidemio-Clinical Study. J Assoc Physicians India. 2020:13-9.

Tambe MP, Parande MA, Tapare VS, BorlePS, Lakde RN, Shelke SC, BJMC COVID Epidemiology group. Anepidemiological study of laboratory confirmed COVID-19 cases admittedin a tertiary care hospital of Pune, Maharashtra. Indian J Public Health. 2020;64:183-7.

Yadaw AS, Li YC, Bose S, Iyengar R, Bunyavanich S, Pandey G. Clinical features of COVID-19 mortality: development and validation of a clinical prediction model. Lancet Digi Health. 2020;2(10):516-25.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020.

Kansara N, Nandapurkar AB, Maniyar R, Yadav AK. Prediction of mortality by age and multi-morbidities among confirmed COVID-19 patients: Secondary analysis of surveillance data in Pune, Maharashtra, India. Indian J Public Health. 2021;65:64-6.

Joshi SR. Indian COVID-19 Risk Score, Comorbidities and Mortality. J Assoc Phys India. 2020;68:11.

Mishra V, Burma AD, Das SK, Parivallal MB, Amudhan S, Rao GN. COVID-19 Hospitalized Patients in Karnataka: Survival and Stay Characteristics. Indian J Public Health. 2020;64:221-4.

Du RH, Liang LR, Yang CQ, Wang W, Cao TZ, Li M, Guo GY, Du J, Zheng CL, Zhu Q, Hu M. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J. 2020;55(5).

Porcheddu R, Serra C, Kelvin D, Kelvin N, Rubino S. Similarity in case fatality rates (CFR) of COVID-19/SARS-COV-2 in Italy and China. The Journal of Infection in Developing Countries. 2020;14(2):125-8.

Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-42.

Wortham JM. Characteristics of persons who died with COVID-19—United States, February 12–May 18, 2020. MMWR. Morbid Mortal Weekly Rep. 2020;69.

Majeed J, Ajmera P, Goyal RK. Delineating clinical characteristics and comorbidities among 206 COVID-19 deceased patients in India: Emerging significance of renin angiotensin system derangement. Diabet Res Clin Pract. 2020;167:108349.

Orioli L, Hermans MP, Thissen JP, Maiter D, Vandeleene B, Yombi JC. COVID-19 in diabetic patients: related risks and specifics of management. Annal Endocrinol. 2020.

Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and diabetes: Knowledge in progress. Diabet Res Clin Pract. 2020:108142.

Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia–a systematic review, meta-analysis, and meta-regression. Diabet Metab Syndr. 2020.

Espinosa OA, Zanetti ADS, Antunes EF, Longhi FG, Matos TA, Battaglini PF. Prevalence of comorbidities in patients and mortality cases affected by SARS-CoV2: a systematic review and meta-analysis. Rev Inst Med Trop Sao Paulo. 2020;62:43.

Singh AK, Misra A. Impact of COVID-19 and comorbidities on health and economics: Focus on developing countries and India. Diabet Metab Syndr. 2020;14(6):1625-30.

Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, Liu XQ, Chen RC, Tang CL, Wang T, Ou CQ. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. Eur Respir J. 2020;55(5).

Kunal S, Gupta K, Sharma SM, Pathak V, Mittal S, Tarke C. Cardiovascular system and COVID-19: perspectives from a developing country. Monaldi Arch Chest Dis. 2020;90(2).

Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in COVID-19. N Engl J Med. 2020.

Singh AK, Gupta R, Misra A. Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers. Diabetes Metab Syndr. 2020;14(4):283-7.

Dan S, Pant M, Upadhyay SK. The Case Fatality Rate in COVID-19 Patients With Cardiovascular Disease: Global Health Challenge and Paradigm in the Current Pandemic. Curr Pharmacol Rep. 2020:1-10.

Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, Li J, Yao Y, Ge S, Xu G. Kidney disease is Aassociated with in-hospital death of patients with COVID-19. Kidney Int. 2020.

Ministry of Health and Family Welfare, Government of India. Directorate General of Health Services (EMR Division) CLINICAL MANAGEMENT PROTOCOL: COVID-19. Available at Accessed on 15 January 2021.




How to Cite

Dhikale, P. T., Chavhan, S. S., Adsul, B. B., Kinge, K. V., Gokhale, C. N., & Ingale, A. R. (2021). Predictors for mortality of inpatients of COVID-19 in Mumbai. International Journal Of Community Medicine And Public Health, 8(6), 3079–3083.



Original Research Articles